The DOI matches its Crossref record.
Long‐term prospective trial of low‐dose methotrexate in rheumatoid arthritis
Abstract
Twenty‐six patients with severe rheumatoid arthritis who had completed a randomized crossover trial of methotrexate elected to continue to receive the drug in a long‐term prospective study. At 36 months, 16 patients remained in the study. Over this period of time, significant improvement was noted in the number of painful and swollen joints, physician and patient global assessments, erythrocyte sedimentation rate, and prednisone dose. Adverse reactions occurred in 16 patients (62%), including nausea, alopecia, headache, stomatitis, herpes zoster, and diarrhea. Mild leukopenia (3 patients), thrombocytopenia (3 patients), and elevated transaminase levels (8 patients) resolved with temporary drug discontinuation. No patient withdrew due to drug toxicity. Liver biopsy specimens in 17 patients after 24 months of treatment showed no evidence of fibrosis or cirrhosis. A significant increase in the percentage of T3 and T4 blood cells and increases in lymphocyte proliferation to concanavalin A and purified protein derivative of tuberculin were found after 2 years of therapy. Our findings indicate that methotrexate has remained effective over 36 months of therapy, with acceptable toxicity levels and no evidence of systemic immunosuppression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis
Bathon, J. M., Martin, R. W., Fleischmann, R. M., Tesser, J. R., Schiff, M. H., Keystone, E. C., Genovese, M. C., Wasko, M. C., Moreland, L. W., Weaver, A. L., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011303432201 · Cited by 1,730
Salliot, C., & van der Heijde, D. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.093690 · Cited by 673
Methotrexate for Rheumatoid Arthritis
Kremer, J. M., Alarcón, G. S., Lightfoot, R. W., Willkens, R. F., Furst, D. E., Williams, H. J., Dent, P. B., & Weinblatt, M. E. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780370304 · Cited by 607
Self-citationGiannini, E. H., Brewer, E. J., Kuzmina, N., Shaikov, A., Maximov, A., Vorontsov, I., Fink, C. W., Newman, A. J., Cassidy, J. T., & Zemel, L. S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199204163261602 · Cited by 588
Low-Dose Methotrexate: A Mainstay in the Treatment of Rheumatoid Arthritis
Cronstein, B. N. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.2.3 · Cited by 535
Methotrexate and histologic hepatic abnormalities: A meta-analysis
Whiting-O'Keefe, Q. E., Fye, K. H., & Sack, K. D. (1991) · The American Journal of Medicine · doi:10.1016/s0002-9343(05)80060-9 · Cited by 358
VAN DEN HOOGEN, F. H. J., BOERBOOMS, A. M. T., SWAAK, A. J. G., RASKER, J. J., VAN LIER, H. J. J., & VAN DE PUTTE, L. B. A. (1996) · Rheumatology · doi:10.1093/rheumatology/35.4.364 · Cited by 355
“In low dosages it has shown favourable effects in the treatment of autoimmune diseases such as rheumatoid arthritis (RA) [ 23-27 ] and dermato- and polymyositis [28, 29].”
BackgroundMethotrexate in Rheumatoid Arthritis
(1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-2-418 · Cited by 345
THE MECHANISM OF ACTION OF METHOTREXATE
Cronstein, B. N. (1997) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(05)70358-6 · Cited by 312
Hepatotoxicity of Chemotherapy
Floyd, J., Mirza, I., Sachs, B., & Perry, M. C. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.11.002 · Cited by 279
Molecular therapeutics. Methotrexate and its mechanism of action
Cronstein, B. N. (1996) · Arthritis & Rheumatism · doi:10.1002/art.1780391203 · Cited by 265
Gamma linolenic acid treatment of rheumatoid arthritis. A randomized, placebo-controlled trial
Zurier, R. B., Rossetti, R. G., Jacobson, E. W., Demarco, D. M., Liu, N. Y., Temming, J. E., White, B. M., & Laposata, M. (1996) · Arthritis & Rheumatism · doi:10.1002/art.1780391106 · Cited by 217
Use of methotrexate in the management of sight-threatening uveitis
Bom, S., Zamiri, P., & Lightman, S. (2001) · Ocular Immunology and Inflammation · doi:10.1076/ocii.9.1.35.3983 · Cited by 55
Metadata
- Authors
- Weinblatt, M. E., Trentham, D. E., Fraser, P. A., Holdsworth, D. E., Falchuk, K. R., Weissman, B. N., & Coblyn, J. S.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 1988-02
- Volume
- 31
- Issue
- 2
- Pages
- 167-175
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2076669590
- Cited by
- 229
- References
- 0
- FWCI
- 19.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.